Emerging as a promising breakthrough in the fight against obesity, the drug is attracting considerable interest . It combines effects of two recognized GLP-1 receptor agonists, semaglutide , plus an new glucose-dependent hormonal component. Early clinical data have demonstrated impressive weight loss in people with a high BMI , perhaps offering a b